“Superbugs were evolving in ways we never expected, creating thousands of enzymes to chop up and destroy antibiotics. They were also developing molecular machinery known as efflux pumps (microscopic vacuum cleaners) to excrete antibiotics, rendering the drugs useless. With a single mutation, bacteria can spoil the chemists’ recipe, and the delicately designed antibiotic is ruined.”
These mutations are difficult to detect, sometimes they are not even picked up on until the autopsy. This is just one of the fascinating facts in this book. We follow McCarthy as he battles to gain IRB approval to carry out to his experimental dalba study. And then he has to source a number of volunteers to submit to the trial. His almost boyish admiration for his exceptional mentor, Tom Walsh, is also a recurring theme throughout this book.
This switches between major medical discoveries, past case studies and McCarthy’s progress in tracking down patients who qualify for his new drug. We learn about all sorts of fascinating people and events like Alexander Fleming in France 1914 and his discovery of penicillin later on, Gerhard Domagk, even J D Rockefeller. Though McCarthy mistakenly claims at one point that the Spanish Flu originated in Iberia, “the outbreak had begun in Spain in May of that year.” When in actual fact that myth was dispelled years ago and most experts currently believe that the flu either started in France, China or the US.
We learn that the 1950s were the golden era for antibiotic development as much as half of the drugs in use today were discovered in this period. He explains the reasons why Big Pharma is always reluctant to invest in antibiotics, is because broadly speaking they know that they will eventually develop drug resistance. They are usually given in short courses and prescribed only when someone is sick, so they don’t like to invest in them.
“The indiscriminate use of antibiotics in animals has been one of the primary drivers of superbugs.” He later expands, saying “The spread of superbugs is driven largely by improper animal husbandry, poor sanitation, weak infection-control policies, and overcrowding.”
Apparently the medical profession had the largest proportion of Nazi party members of any profession in all of Germany. He touches on the cruel medical experiments conducted by Nazi doctors during WWII and the ones done by Americans before that with the Tuskegee experiments, where young, poor, black men were exploited as human guinea pigs for syphilis observation under the guidance of Dr Ray Vonderlehr. The men weren’t told they had syphilis, but just told they had “bad blood” Vonderlehr was performing up to 20 spinal taps a day. This was initially only supposed to be a six month trial to run from 1932-33, until fate intervened and it ended up lasting forty years. The men were not denied treatment, they just weren’t offered any. Around 100 men died as a direct result from untreated condition and they unknowingly infected many innocent women and children in their family as a result. The experiment was only stopped when the story broke in 1972.
“Between 2001 and 2013, there were 148 shortages of antibiotics, and doctors across the country resorted to second-class treatment options. Most patients didn’t even know it was happening.”
We learn of the importance of The Beecher Report published in the “New England Journal of Medicine” in 1966 which cited no less than 22 American studies where patients had served as experimental subjects without informed consent which would lead to a change in approach. He also gives us a brief history and vast importance of the FDA within the USA and possibly the most famous case when Frances Oldham Kelsey repeatedly rejected pressure and abuse from Big Pharma to approve Thalidomide, saving thousands and potentially millions of Americans from serious birth defects.
“I think it is a moral requirement to make money when you can.” So insists Nirmal Mulye, the president of Nostrum Pharmaceuticals, when justifying his decision to increase the price of one of WHO’s list of essential medicines by 400%. But of course it is not that uncommon for pharmaceutical companies to make price increases by more than 5000%. Just because they can get away with it. But it is not all bad news as we find out that GSK in Europe have rewarded their employees for helping doctors prescribe antibiotics appropriately rather than for just meeting sales quotas.
I really enjoyed this book. Like many good popular science books, this was both a terrifying and inspiring read. It avoided all the potential pitfalls of popular medicine books, managing not to be too dumbed down or over-run with jargon. This was a clear, informative and entertaining read.